Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Shanghai Hile Bio-Technology Co's PB Ratio or its related term are showing as below:
SHSE:603718'
s PB Ratio Range Over the Past 10 Years
Min: 1.92 Med: 7.17 Max: 30.6
Current: 2.14
During the past 13 years, Shanghai Hile Bio-Technology Co's highest PB Ratio was 30.60. The lowest was 1.92. And the median was 7.17.
SHSE:603718's PB Ratio is ranked better than 61.22% of 1217
companies
in the Biotechnology industry
Industry Median: 2.86
vs SHSE:603718: 2.14
During the past 12 months, Shanghai Hile Bio-Technology Co's average Book Value Per Share Growth Rate was -43.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 0.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 1.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Shanghai Hile Bio-Technology Co was 14.90% per year. The lowest was -8.80% per year. And the median was 4.25% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Shanghai Hile Bio-Technology Co PB Ratio Related Terms
Shanghai Hile Bio-Technology Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603718 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Shanghai Hile Bio-Technology Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Hile Bio-Technology Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Hile Bio-Technology Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai Hile Bio-Technology Co's PB Ratio falls into.
Shanghai Hile Bio-Technology Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Shanghai Hile Bio-Technology Co (SHSE:603718) has a PB Ratio of 2.14 as of Aug. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Hile Bio-Technology Co and its competitors. This is 70% below median its historical median of 7.17. Over the past decade, Shanghai Hile Bio-Technology Co's PB Ratio has ranged from 1.92 to 30.60. According to the industry distribution chart, Shanghai Hile Bio-Technology Co ranks #472 out of 1217 companies in the Biotechnology industry, placing it in the top 38.8%.
Is Shanghai Hile Bio-Technology Co's PB Ratio too high?
Shanghai Hile Bio-Technology Co's current PB Ratio of 2.14 is 70% below median its 10-year median of 7.17. Over the past 10 years, this metric has ranged from a low of 1.92 to a high of 30.60. The Biotechnology industry median PB Ratio is 2.86. Shanghai Hile Bio-Technology Co's value of 2.14 is 25.2% below this industry median. Based on the distribution chart, Shanghai Hile Bio-Technology Co ranks #472 out of 1217 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Hile Bio-Technology Co has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shanghai Hile Bio-Technology Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Hile Bio-Technology Co ranks #472 out of 1217 companies for PB Ratio. This puts Shanghai Hile Bio-Technology Co in the upper half of its industry. The industry median PB Ratio is 2.86. Shanghai Hile Bio-Technology Co's value of 2.14 is 25.2% below this benchmark. Historically, Shanghai Hile Bio-Technology Co's own PB Ratio has ranged from 1.92 to 30.60 over the past decade. While the company's 10-year median is 7.17 vs. the industry median of 2.86, Shanghai Hile Bio-Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.86, based on 1,217 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Hile Bio-Technology Co's current PB Ratio of 2.14 is 25.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Hile Bio-Technology Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Hile Bio-Technology Co's current PB Ratio is 2.14, which is 70% below median its own 10-year median of 7.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Hile Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Hile Bio-Technology Co (SHSE:603718) is currently considered Possible Value Trap. The stock's GF Value™ is ¥4.22, compared to a current price of ¥2.91 — trading 31% below its estimated fair value. The current PB Ratio is 2.14, which is 70% below median its 10-year median of 7.17 and 25.2% below the Biotechnology industry median of 2.86. Shanghai Hile Bio-Technology Co's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Shanghai Hile Bio-Technology Co (SHSE:603718), the current PB Ratio is 2.14 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Hile Bio-Technology Co (SHSE:603718) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Hile Bio-Technology Co stock appears to be undervalued.
The current stock price of ¥2.91 is trading 31% below its estimated GF Value™ of ¥4.22.
GuruFocus considers Shanghai Hile Bio-Technology Co to be Possible Value Trap.
Key valuation signals for SHSE:603718:
PB Ratio: 2.14 (70% below median its 10-year median of 7.17)
GF Value™: ¥4.22 vs. price of ¥2.91 (31% below fair value)
Industry Position: 25.2% below the Biotechnology median (#472 of 1217)
No single metric tells the full story. See the SHSE:603718 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Hile Bio-Technology Co Ltd is a veterinary biological product manufacturer integrating research and development, production, sales, and service. The company has over 40 categories of poultry, livestock, and pets. The company provides services for the prevention of livestock diseases, improving the health of livestock and poultry, and improving the production efficiency of farmers, and is able to provide comprehensive solutions and an authoritative veterinary expert service system.
50GF Score
Get the complete analysis for SHSE:603718
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603718 has been successfully added to your 
